c-Abl regulates p53 levels under normal and stress conditions by preventing its nuclear export and ubiquitination

Molecular and Cellular Biology

Volumn 21, Issue 17, 2001, Pages 5869-5878

  Vogt Sionov, R ^a   Coen, S ^a   Goldberg, Z ^a   Berger, M ^a   Bercovich, B ^a   Ben Neriah, Y ^a   Ciechanover, A ^a   Haupt, Y ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; DNA; PROTEASOME; PROTEIN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; DNA DAMAGE; FIBROBLAST; HELA CELL; HUMAN; HUMAN CELL; INTRACELLULAR TRANSPORT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; STRESS; UBIQUITINATION; WART VIRUS;

ACTIVE TRANSPORT, CELL NUCLEUS; CELL LINE; CELL NUCLEUS; CYTOPLASM; DNA DAMAGE; FIBROBLASTS; HELA CELLS; HUMANS; LIGASES; NUCLEAR PROTEINS; ONCOGENE PROTEINS, VIRAL; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-MDM2; REPRESSOR PROTEINS; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-CONJUGATING ENZYMES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINS;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPES;

EID: 0034898859     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.21.17.5869-5878.2001     Document Type: Article

References (52)

1. Regulation of p53 stability
2. Ataxia telangiectasia mutant protein activates c-Abl tyrosine kinase in response to ionizing radiation
3. Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome
4. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
5. An intact Hdm2 RING-finger domain is required for nuclear exclusion of p53
6. Functional p53 protein in human papillomavirus-positive cancer cells
7. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage
8. Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation
9. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens
10. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6
11. The Mdm2 RING-finger domain is required to promote p53 nuclear export
12. The complexity of p53 modulation: Emerging patterns from divergent signals
13. p53 dependent growth suppression by the c-Abl nuclear tyrosine kinase
14. Identification of the ubiquitin carrier proteins, E2s, involved in signal-induced conjugation and subsequent degradation of IkBa
15. Cell type-specific inhibition of p53-mediated apoptosis by mdm2
16. Mdm2 promotes the rapid degradation of p53
17. The ubiquitin system
18. ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53
19. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53
20. p53 regulation by post-translational modification and nuclear retention in response to diverse stresses
21. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents
22. Determination of cell fate by c-Abl activation in the response to DNA damage
23. Inhibition of p53-mediated transactivation by E6 of type 1, but not type 5, 8, or 47, human papillomavirus of cutaneous origin
24. Regulation of p53 stability by Mdm2
25. Inhibition of p53 DNA binding by human papillomavirus E6 proteins
26. Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription
27. High-risk human papillomavirus E6 protein has two distinct binding sites within p53 of which only one determines degradation
28. Three distinct signalling responses by murine fibroblasts to genotoxic stress
29. Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines
30. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage
31. p53 in complex with DNA is resistant to ubiquitin-dependent proteolysis in the presence of HPV-16 E6
32. MDM2-master regulator of the p53 tumor suppressor protein
33. Stimulation of p53 DNA binding by c-Abl requires the p53 C terminus and tetramerization
34. p53-dependent growth arrest following calcium phosphate-mediated transfection of murine fibroblasts
35. Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein
36. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines Proc
37. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
38. Interaction between ATM protein and c-Abl in response to DNA damage
39. c-Abl: Activation and nuclear targets
40. Tumor surveillance via the ARF-p53 pathway
41. The human homologs of checkpoint kinases Chkl and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites
42. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking
43. Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation
44. The role of the E6-53 interaction in the molecular pathogenesis of HPV
45. The cellular response to p53: The decision between life and death
46. c-Abl neutralizes the inhibitory effect of Mdm2 on p53
47. The cytostatic function of c-Abl is controlled by multiple nuclear localization signals and requires the p53 and Rb tumor suppressor gene products
48. Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53
49. Regulation of DNA damage-induced apoptosis by the c-Abl tyrosine kinase
50. Role for c-Abl tyrosine kinase in growth arrest response to DNA damage
51. Role for p300 in stabilization of p53 in the response to DNA damage
52. The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300